Tectonic Therapeutic, Inc.
TECX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TECX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TECX
Tectonic Therapeutic, Inc. (TECX) is a clinical-stage biotechnology company focused on discovering and developing novel therapeutic candidates, with its lead product candidate TX45 and other pipeline programs. As of June 30, 2026, the company reported cash and equivalents of $227.6 million and expects this to fund operations for at least the next twelve months.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 2 clinical trials for Tectonic Therapeutic, Inc..
Tectonic Therapeutic, Inc. (TECX) is a clinical-stage biotechnology company focused on discovering and developing novel therapeutic candidates, with its lead product candidate TX45 and other pipeline programs. As of June 30, 2026, the company reported cash and equivalents of $227.6 million and expects this to fund operations for at least the next twelve months.
- Cash and equivalents of $227.6M as of 2026-06-30 [sec].
- Net loss of $22.3M for the quarter ended 2026-06-30 [sec].
- Shareholders' equity of $283.8M as of 2026-06-30 [sec].
- Lead product candidate is TX45, with ongoing research and clinical development [sec_mda · as of 2024-11-12].
- Company has never generated revenue from product sales and has an accumulated deficit of $136.2M as of September 30, 2024 [sec_mda · as of 2024-11-12].
What works
- Cash position of $227.6M as of 2026-06-30 provides a runway of at least twelve months to fund operating expenses and capital expenditures [sec_mda · as of 2026-08-06].
- Company has raised significant capital through equity financings, including $177.3M in net proceeds from an ATM offering in early 2025 [sec_mda · as of 2026-05-07].
- Focus on a lead candidate TX45 and a pipeline of additional programs suggests multiple shots on goal [sec_mda · as of 2024-11-12].
What to weigh
- No approved products and no revenue from product sales to date; company relies entirely on external financing [sec_mda · as of 2024-11-12].
- Accumulated deficit of $136.2M as of September 30, 2024, with expectations of continued significant expenses and operating losses [sec_mda · as of 2024-11-12].
- Future capital requirements depend on many uncertain factors, including clinical trial outcomes and regulatory timelines, creating potential need for additional financing [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Company expects existing cash to fund operations for at least twelve months
“We expect our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months.”
SEC MD&A · August 6, 2026
Accumulated deficit of $136.2M as of September 30, 2024
“As of September 30, 2024, we had an accumulated deficit of $136.2 million.”
SEC MD&A · November 12, 2024
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Company has never generated product revenue and relies on external financing to fund operations [sec_mda · as of 2024-11-12].
- Significant accumulated deficit — Accumulated deficit of $136.2M as of September 30, 2024, with continued losses expected [sec_mda · as of 2024-11-12].
- Dependence on clinical and regulatory success — Future capital needs depend on clinical trial results, regulatory approvals, and program prioritization [sec_mda · as of 2026-08-06].
- Need for additional capital — Company will need additional funding to support ongoing R&D and potential commercialization [sec_mda · as of 2024-11-12].
What to watch
- Progress of lead candidate TX45 through clinical development [sec_mda · as of 2024-11-12].
- Any updates on cash runway or additional financing activities [sec_mda · as of 2026-08-06].
- Initiation of preclinical studies or clinical trials for other pipeline candidates [sec_mda · as of 2024-11-12].
- Regulatory milestones or interactions that could affect development timelines [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Tectonic Therapeutic, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tectonic Therapeutic, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
32.0 months
D/E 0.06 · 0% dilution
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
0 buys · 9 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
108
Total value held
$321.2M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 2,816,494 | $87.1M |
| vanguard capital management llc | 947,064 | $29.3M |
| blackrock, inc. | 860,352 | $26.6M |
| braidwell lp | 847,151 | $26.2M |
| baker bros. advisors lp | 607,788 | $18.8M |
| susquehanna international group, llp | 293,475 | $9.1M |
| kennedy capital management llc | 286,682 | $8.9M |
| geode capital management, llc | 268,273 | $8.3M |
| marshall wace, llp | 229,595 | $7.1M |
| orbimed advisors llc | 226,600 | $7.0M |
Showing top 10 of 108 institutional holders of Tectonic Therapeutic, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 22.6%
- Days to cover
- 7.5
- Shares short
- 2,413,729
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TECX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Tectonic Therapeutic, Inc.?
Tectonic Therapeutic, Inc. (TECX) is a clinical-stage biotechnology company focused on discovering and developing novel therapeutic candidates, with its lead product candidate TX45 and other pipeline programs. As of June 30, 2026, the company reported cash and equivalents of $227.6 million and expects this to fund operations for at least the next twelve months.
What is Tectonic Therapeutic, Inc.'s lead drug candidate?
Tectonic Therapeutic, Inc.'s most advanced tracked candidate is tx000045 (Phase 2) for Hypertension, Pulmonary.
Who is the CEO of Tectonic Therapeutic, Inc.?
Dr. Alise S. Reicin M.D., Ph.D. is the chief executive officer of Tectonic Therapeutic, Inc. (TECX).
Where is Tectonic Therapeutic, Inc. headquartered?
Tectonic Therapeutic, Inc. (TECX) is headquartered in Watertown, MA, United States.
What therapeutic areas does Tectonic Therapeutic, Inc. focus on?
Tectonic Therapeutic, Inc. develops therapies across Cardiovascular, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.